CTOs on the Move

Health Fuse

www.healthfuse.com

 
Health Fuse is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 5K-10K
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details

Similar Companies

Cancer Care Center of Jackson

Cancer Care Center of Jackson is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Jackson, TN. To find more information about Cancer Care Center of Jackson, please visit www.cancercarecenter.org

Tethys Bioscience

Tethys Bioscience is a personalized predictive medicine company developing novel tests which address the growing global healthcare challenge of chronic diseases such as diabetes.

Haynes Ambulance Of Alabama

Haynes Ambulance Of Alabama is a Montgomery, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Luminis Health

Established in 2019 when Anne Arundel Medical Center and Doctors Community Medical Center came together to form one health system, Luminis Health is sparking a new path forward. With 595 beds across three hospitals, we currently serve seven counties in the heart of central Maryland. Our team is made up of more than 9,000 medical staff, employees and volunteers – all of whom are committed to illuminating new possibilities in health care and for our community. Thanks to them, U.S. News & World Report has deemed AAMC a top hospital in the region and the Maryland Institute for Emergency Medical Services Systems has named DCMC a primary stroke center – just to name a few accolades. We have also earned national recognition in cancer care, stroke care, innovation and patient satisfaction. We can`t wait to see what`s next.

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.